LFMD

$4.44

Post-MarketAs of Mar 17, 8:00 PM UTC

LifeMD, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.44
Potential Upside
5%
Whystock Fair Value$4.66
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryHealth Information Services

LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platf...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$213.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-131.16%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.11

Recent News

Simply Wall St.
Mar 13, 2026

A Look At LifeMD (LFMD) Valuation After Profitability Return And 2026 Growth Guidance

LifeMD (LFMD) is back on investors’ radar after reporting Q4 and full year 2025 earnings, swinging to net income and pairing those results with fresh 2026 revenue guidance and product expansion updates. See our latest analysis for LifeMD. That earnings swing and new 2026 guidance have come after a sharp rebound in the share price, with a 31.17% 7 day share price return and 29.02% 30 day share price return, even though the 1 year total shareholder return remains down 30.48%. If LifeMD’s recent...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 10, 2026

LifeMD Inc (LFMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

LifeMD Inc (LFMD) reports robust financial performance with a 25% annual revenue increase and strategic advancements in AI and healthcare services.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 9, 2026

LifeMD Q4 Earnings Call Highlights

LifeMD (NASDAQ:LFMD) executives highlighted strong fourth-quarter and full-year 2025 performance and outlined investment priorities for 2026, pointing to accelerating demand in its weight management business, expansion into women’s health, and continued momentum in men’s health. Management said the

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 9, 2026

LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates

LifeMD (LFMD) delivered earnings and revenue surprises of -300.00% and +5.92%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 18, 2026

Medifast Q4 Earnings Call Highlights

Medifast (NYSE:MED) reported fourth-quarter and full-year 2025 results while outlining continued efforts to reposition the business around metabolic health, highlighting early signs of improving coach productivity even as revenue and the active earning coach base declined sharply. Leadership transi

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.